What is a peptide? From amino acids to medicines
In short
About 7 minutes for the short version; 14 with every detail open.
- A peptide is a short chain of small building blocks called amino acids.
- The body uses peptides to send messages. Insulin is one of them.
- Size matters. It decides how fast the kidneys clear a peptide, and if it gets through the gut.
- Chemists change peptides so the body does not break them down so fast.
- A peptide can be natural and still cause harm. Natural says nothing about safety.
Each section starts with the short answer. The rest is folded under “In detail”.
This page explains what a peptide physically is, from first principles. It is the foundation for the rest of the site: how peptides act on cells, how long they last in the body, and why most are injected.
From amino acid to chain
What is a peptide made of?
- One amino acid. A small molecule with an amino end, an acid end and a side chain. The side chain is what makes each of the 20 kinds different.
- Two join. The amino end of one reacts with the acid end of the next. The link is called a peptide bond.
- A short chain. More amino acids are added, one after the other. A chain of a few to about 50 is usually called a peptide.
- A long chain. Longer chains are called polypeptides. They fold into a fixed shape and form proteins.
Every peptide medicine on this site is such a chain. What it does depends on which amino acids sit where, and on the shape the chain takes.4
In detail: The chemistry of the link, and why order matters , about 1 minute to read
Every amino acid carries two reactive groups: an acid (carboxylic) group and a basic (amino) group. When the amino group of one amino acid reacts with the acid group of another, the bond between them makes a dipeptide.1 Chemists call this joining a condensation, because a molecule of water is given off. Digestion runs the same reaction backwards: enzymes in the gut cut the peptide bond by adding water back, which is called hydrolysis.5,6
A chain therefore has two different ends: the amino end (N-terminus) and the acid end (C-terminus). A sequence is written as a row of three-letter codes that follow international naming rules, and regulators ask makers to mark both ends and any changes to them.4 BPC-157, for example, is written Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val: fifteen amino acids in a row.7
There are 20 different amino acids in proteins, and in a natural protein their order is written in a gene.3 Order is everything. It has long been accepted that the sequence of amino acids is what gives each protein its own chemical and physiological properties.8 Two chains with the same amino acids in a different order are different molecules.
Where “peptide” ends and “protein” begins
When is a chain a peptide, and when is it a protein?
| Who | Where they draw the line | Insulin (51 amino acids, two chains) is called |
|---|---|---|
| US genome institute (NHGRI) glossary | Peptide: a chain of typically 2 to 50 amino acids. A chain of 51 or more: polypeptide | Not named; the glossary counts one chain at a time |
| US Food and Drug Administration (FDA) rule | Protein: more than 40 amino acids, counting all chains together | A protein, regulated as a biological product since 23 March 2020 |
| Nobel Prize presentation speech, 1958 | No number given | A protein |
| A 2022 review of peptide medicines | Usually 500–5000 daltons | A peptide |
| A 2013 review of peptide medicines | Fewer than 50 amino acids and under 10,000 daltons | Unclear: too many amino acids in total, but light enough |
The line is a convention, not a property of nature. A review of oral peptide medicines notes that insulin, at 51 amino acids, is described as either.5 The word “peptide” therefore tells you about size, not about what a molecule does or how risky it is.
In detail: Why the line matters to regulators, and not to your body , about 1 minute to read
In the United States the line has legal weight. A federal rule defines a protein as an amino acid chain of more than 40 amino acids, and counts chains that belong together as one.9 Insulin, with 51 amino acids in two chains, therefore moved from the drug rules to the rules for biological products on 23 March 2020.10 The molecule did not change; only the paperwork did.
Your body does not use either word. How well a molecule binds its target depends on its chemistry and its shape, whatever it is called.6 In the same way, “peptide” is not a quality mark. It covers tested medicines such as semaglutide, experimental molecules such as BPC-157, and deadly natural toxins (see the last section of this page).
Shape: from chain to folded molecule
Does a peptide have a shape?
| Level | What it is | Held together by |
|---|---|---|
| Primary structure | The order of the amino acids | Peptide bonds |
| Secondary structure | Local twists and pleats of the backbone, such as a helix or a flat sheet | Mainly hydrogen bonds |
| Tertiary structure | The whole chain folded in three dimensions | Contacts between side chains, sometimes sulfur bridges (disulfide bonds) |
| Quaternary structure | Two or more chains working as one unit | Contacts or bonds between the chains |
Source 4
Large proteins fold into stable shapes. Many short peptides are floppy: they lack the support of a stable fold, which leaves their bonds exposed to enzymes.11 Acid can also unfold some proteins, which is one reason the stomach is hostile to them.5
In detail: Examples of shape in medicines , about 1 minute to read
- Insulin is two chains held together. The Nobel committee described in 1958 how Frederick Sanger worked out the order of its 51 amino acids and showed that it has two different chains, joined by two bridges of sulfur atoms.8
- Dulaglutide (Trulicity) is built from two identical chains linked by disulfide bonds. Each chain carries a GLP-1-like peptide joined to part of an antibody.13
- Ring-shaped peptides. Chemists can close a chain into a ring. A ring helps a short peptide hold a helix or a turn that it could not keep on its own.11
Size: why the weight of a molecule matters
Why does size matter?
| Molecule | What it is | Weight (daltons) |
|---|---|---|
| Orforglipron | A small-molecule medicine (not a peptide) that acts like GLP-1 | 883 |
| BPC-157 | A chain of 15 amino acids | 1,419.5 |
| Semaglutide | A changed version of the gut hormone GLP-1, with a fatty side chain | about 4,114 |
| Insulin | 51 amino acids in two chains | about 5,808 |
One dalton is roughly the weight of one hydrogen atom. A widely used rule of thumb from drug chemistry says that poor absorption is more likely when a molecule weighs more than 500 daltons.17 Every molecule in the table is above that.
In detail: Size, the kidneys and the immune system , about 2 minutes to read
Getting through barriers
Many pills are small molecules, and small size helps a medicine pass through cell membranes.17 Natural peptides are typically large, water-loving and poorly able to cross membranes, and they are cleared quickly.18 That is why most peptides work on receptors on the outside of cells (see how signalling works) and why most are injected (see why not a pill).
The kidney filter
The kidney’s filter (the glomerulus) holds molecules back by size and electrical charge. It lets only small amounts of albumin, a large blood protein, through.19 Peptides are generally small enough to be filtered freely.12 Fast clearance by the kidneys, together with breakdown by enzymes, is a common reason why peptides have short half-lives.20 Chemists use this: a peptide that clings to albumin, or that is fused to a large protein, becomes too big to pass the filter easily (see pharmacokinetics).11
The immune system
Medicines can provoke antibodies against themselves. Small peptides usually provoke fewer antibodies than larger protein medicines, but antibodies against the drug have been reported for some peptide medicines.11,12 Clumps of protein (aggregates) can make an immune response more likely.21 Makers design against this: dulaglutide was engineered to reduce its immune potential, and its EU label credits its close likeness to the body’s own molecules.13
How chemists make peptides last
How do chemists stop a peptide being cut up?
| Trick | What it does | Example in an authorised medicine |
|---|---|---|
| Swap in a mirror-image amino acid (D-form) | Enzymes are built to fit the normal L-form, so a D-form at a cutting site blocks them | Leuprolide carries a D-leucine; octreotide carries D-phenylalanine and D-tryptophan |
| Close the chain into a ring | Fewer loose ends for enzymes; a more rigid shape | Octreotide (a ring held by a sulfur bridge) |
| Cap the ends | Resists enzymes that cut from the end of a chain | Leuprolide’s modified end group |
| Swap the amino acid an enzyme targets | The enzyme DPP-4 can no longer cut the chain | Semaglutide (Aib at position 8) |
| Add a fatty-acid chain | The peptide clings to albumin, which the kidney filter mostly holds back | Liraglutide, semaglutide |
| Fuse to part of an antibody, or attach polyethylene glycol (PEG) | The molecule becomes too big to filter and is shielded from enzymes | Dulaglutide (antibody part) |
Sources 22, 23, 24, 20, 12, 25, 26, 27, 19, 13, 28, 11
Each trick trades something. A D-amino acid can protect a peptide but often weakens its effect.11 Semaglutide binds its receptor about three times less tightly than its predecessor liraglutide, a loss its designers accepted for stronger albumin binding.25
In detail: Mirror-image amino acids, and two worked examples , about 2 minutes to read
Left- and right-handed amino acids
Except for glycine, every natural amino acid exists in two mirror-image forms, like a left and a right hand (the L-form and the D-form). Natural amino acids have the L-form.4 The body’s protein-cutting enzymes are shaped to fit L-chains, so putting a D-form at the spot where an enzyme cuts is an effective way to extend a peptide’s life in the blood.11
Octreotide: four tricks in eight amino acids
The natural hormone somatostatin has a half-life of only a few minutes in the blood.20 Octreotide is a shortened copy of eight amino acids. It carries two D-amino acids, is closed into a ring by a sulfur bridge, and ends in an altered amino acid.23,24 In laboratory tests it resisted pure enzymes and tissue extracts (Evidence level: Shown in cells or tissue in the laboratory), and in rats and rhesus monkeys it acted much longer than somatostatin (Evidence level: Shown in animal studies).23 A review gives its plasma half-life as about 1.5 hours, against a few minutes for somatostatin.20
Semaglutide: three changes to a natural hormone
Natural GLP-1 has a half-life of about 1.5 to 2 minutes in the blood.13 Semaglutide changes two amino acids (one to block the enzyme DPP-4) and adds a fatty-acid side chain that binds albumin; in people its half-life is about one week.25,26 How half-life shapes everything else is explained on the pharmacokinetics page.
How peptides are made, and what each method leaves behind
How are peptide medicines made?
| Chemical synthesis on a solid support | Made by microbes (recombinant) | |
|---|---|---|
| How it works | The first amino acid is fixed to tiny resin beads. Protected amino acids are added one at a time, with washing between steps. The finished chain is cut free. | A gene for the chain is put into bacteria or yeast, which build it. The chain is then purified. |
| Typical leftovers | Chains with an amino acid missing (deletion sequences), cut short or doubled; mirror-image errors; leftover chemicals and solvents | Material from the host cells, such as their proteins and DNA; toxins from bacteria (endotoxin) |
| Examples | Most synthetic peptides | Human insulin (the first medicine of this kind); the semaglutide backbone (made in yeast) |
A regulated maker purifies the product and tests it against set limits before release.4 A product from outside the legal supply chain comes with no such guarantee; what labs have found in real vials is on the product risk page.
In detail: Why mistakes build up, and which impurities each method leaves , about 2 minutes to read
Why long chains are hard to make
Small losses at each step add up over a long chain
61%
overall yield after 100 steps, even when each step works 99.5 times in 100
What was counted A worked example in the Nobel Prize press release of 1984; at 90% per step, the overall yield is only 0.003% Source The Nobel Prize in Chemistry 19841
Solid-phase synthesis was developed by Bruce Merrifield, who received the 1984 Nobel Prize in Chemistry for it. Fixing the growing chain to a solid lets chemists wash away by-products after each step instead of purifying every intermediate.1 The arithmetic in the key number explains the main weakness: a step that does not finish leaves some chains with an amino acid missing.4 Making peptides of fewer than about 50 amino acids is now routine; longer chains remain hard to make on a large scale.11
Impurities from chemical synthesis
EU guidance lists the impurities chemists must control:4
- Deletion sequences: chains with one or more amino acids missing, from steps that did not finish.
- Truncated and insertion sequences: chains whose growth was stopped early, or with an amino acid added twice.
- Mirror-image errors (racemisation or epimerisation): an amino acid that flipped to its D-form during the reaction.
- Process chemicals: leftover reagents, solvents and metals.
A review of impurities in peptide medicines adds unwanted counter-ions (salt partners) such as trifluoroacetate and, in poorly made products, contamination with other, unrelated peptides.29 Peptides also break down over time, for example by oxidation or by reacting with water (hydrolysis).4,32
Impurities from recombinant production
Microbes build the chain from its gene, but the raw product contains material from the cells themselves, such as enzymes, DNA and RNA fragments and unrelated proteins.11 When bacteria are used, endotoxin is a particular concern: it is part of the outer wall of some bacteria and a major cause of fever reactions to contaminated medicines.30
Recombinant production made human insulin the first commercial health-care product of this technology, in the early 1980s.31 The EU and US labels for semaglutide state that its peptide is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology.26,33
“Natural” says nothing about safety
If a peptide is natural, is it harmless?
| Natural peptide | Where it comes from | What it can do |
|---|---|---|
| Insulin | Your own pancreas | Keeps you alive. Too much makes blood sugar fall dangerously low |
| Alpha-amanitin | The death cap mushroom | A ring-shaped peptide that destroys the liver; it survives cooking and digestion |
| Exendin-4 | Gila monster venom | The starting point for exenatide, which became an authorised diabetes medicine |
| GnRH (a brain hormone) | Your own brain | Given in pulses, it keeps the sex-hormone system going. Given without a break, it shuts it down |
Sources 34, 35, 36, 37, 11, 38, 39, 22
Effects follow from the dose, the timing and the tissue reached, not from where a molecule was first found.6,39 A product sold as a natural peptide is also a manufactured product, with the impurities described above.
In detail: Three reasons natural is not the same as harmless , about 2 minutes to read
- Amount. Insulin is the body’s own hormone, yet too much causes low blood sugar, with shaking, confusion and, if severe, unconsciousness.34 A Dutch case report describes two people who injected semaglutide obtained without a prescription and came to hospital in a coma with very low blood sugar: the product contained insulin.40
- Pattern. In a study in rhesus monkeys whose own hormone signal had been switched off, hourly pulses of GnRH restored the pituitary’s hormone release, while a constant infusion of the same hormone did not; switching from pulses to a constant infusion could desensitise the pituitary again (Evidence level: Shown in animal studies).39 Leuprolide, a synthetic, modified nine-amino-acid version of GnRH, works this way in people: it first raises sex hormones and then, given continuously, lowers testosterone to castrate levels within two to four weeks. Medicine uses this on purpose, in prostate cancer, for example.22 The same natural signal, delivered in a different pattern, has the opposite effect. The signalling page explains why.
- Nature makes poisons too. The death cap mushroom is involved in most fatal mushroom poisonings worldwide, and alpha-amanitin, a double ring of eight amino acids, is mainly responsible.35,36 It resists heat, acid and enzymes, so cooking and digestion do not destroy it.36
Nature is also a rich source of medicines: exenatide was developed from a peptide found in Gila monster venom.37,11,41 The point is not that natural peptides are dangerous or good. It is that the origin of a molecule tells you neither.
Sources
Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.
In detail: All 41 sources, numbered as in the text , about 6 minutes to read
- (1984). The Nobel Prize in Chemistry 1984: Press release. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026 ↩
- (2026). Peptide — Talking Glossary of Genomic and Genetic Terms. Web page genome.gov (opens an external site) — accessed 22 October 2026 ↩
- (2026). Amino Acids — Talking Glossary of Genomic and Genetic Terms. Web page genome.gov (opens an external site) — accessed 22 October 2026 ↩
- (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026 ↩
- (2021). Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharmaceutica Sinica B 11:2416-2448. Review doi:10.1016/j.apsb.2021.04.001 (opens an external site) ↩
- (2021). Defining and unpacking the core concepts of pharmacology education. Pharmacology Research & Perspectives 9:e00894. Research article doi:10.1002/prp2.894 (opens an external site) ↩
- (2026). PubChem Compound Summary for CID 9941957, BPC-157. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026 ↩
- (1958). The Nobel Prize in Chemistry 1958: Presentation speech. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026 ↩
- (2026). 21 CFR 600.3 – Definitions, paragraph (h)(6): 'protein'. eCFR. Law ecfr.gov (opens an external site) — accessed 22 October 2026 ↩
- (2020). FDA works to ensure smooth regulatory transition of insulin and other biological products. Regulator fda.gov (opens an external site) — accessed 22 October 2026 ↩
- (2022). Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:48. Review doi:10.1038/s41392-022-00904-4 (opens an external site) ↩
- (2013). Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clinical Pharmacokinetics 52:855-868. Review doi:10.1007/s40262-013-0079-0 (opens an external site) ↩
- (2026). Trulicity (dulaglutide): EPAR — product information. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026 ↩
- (2026). PubChem Compound Summary for CID 137319706, Orforglipron. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026 ↩
- (2026). PubChem Compound Summary for CID 56843331, Semaglutide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026 ↩
- (2026). PubChem Compound Summary for CID 118984375, Insulin Human. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026 ↩
- (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46:3-26. Review doi:10.1016/s0169-409x(00)00129-0 (opens an external site) ↩
- (2015). Strategic approaches to optimizing peptide ADME properties. The AAPS Journal 17:134-143. Review doi:10.1208/s12248-014-9687-3 (opens an external site) ↩
- (2008). Properties of the glomerular barrier and mechanisms of proteinuria. Physiological Reviews 88:451-487. Review doi:10.1152/physrev.00055.2006 (opens an external site) ↩
- (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367. Review doi:10.1007/s00726-005-0289-3 (opens an external site) ↩
- (2006). Effects of protein aggregates: an immunologic perspective. The AAPS Journal 8:E501-E507. Review doi:10.1208/aapsj080359 (opens an external site) ↩
- (2026). LUPRON DEPOT (leuprolide acetate for depot suspension): prescribing information. DailyMed. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 22 October 2026 ↩
- (1982). SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 31:1133-1140. Research article doi:10.1016/0024-3205(82)90087-x (opens an external site) ↩
- (2026). PubChem Compound Summary for CID 448601, Octreotide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026 ↩
- (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 58:7370-7380. Research article doi:10.1021/acs.jmedchem.5b00726 (opens an external site) ↩
- (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026 ↩
- (2026). Victoza (liraglutide): EPAR — product information. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026 ↩
- (2003). Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery 2:214-221. Review doi:10.1038/nrd1033 (opens an external site) ↩
- (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 101:2-30. Review doi:10.1016/j.jpba.2014.06.012 (opens an external site) ↩
- (2020). Current technologies to endotoxin detection and removal for biopharmaceutical purification. Biotechnology and Bioengineering 117:2588-2609. Review doi:10.1002/bit.27362 (opens an external site) ↩
- (1983). Human insulin from recombinant DNA technology. Science 219:632-637. Research article doi:10.1126/science.6337396 (opens an external site) ↩
- (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27:544-575. Review doi:10.1007/s11095-009-0045-6 (opens an external site) ↩
- (2026). OZEMPIC (semaglutide) injection — prescribing information (revised 05/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026 ↩
- (2023). Low blood sugar (hypoglycaemia). Web page nhs.uk (opens an external site) — accessed 20 October 2026 ↩
- (2015). Amanita phalloides poisoning: Mechanisms of toxicity and treatment. Food and Chemical Toxicology 86:41-55. Review doi:10.1016/j.fct.2015.09.008 (opens an external site) ↩
- (2021). Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics. Toxins 13:417. Review doi:10.3390/toxins13060417 (opens an external site) ↩
- (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry 267:7402-7405. Research article doi:10.1016/S0021-9258(18)42531-8 (opens an external site) ↩
- (2026). Byetta (exenatide): EPAR — product information (authorisation withdrawn). Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026 ↩
- (1978). Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631-633. Research article doi:10.1126/science.100883 (opens an external site) ↩
- (2026). Insulin intoxications caused by falsified semaglutide. Nederlands Tijdschrift voor Geneeskunde 170:D9116. Research article PMID 42390457 (opens an external site) ↩
- (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery 20:309-325. Review doi:10.1038/s41573-020-00135-8 (opens an external site) ↩